BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 20388793)

  • 1. Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy.
    Grisendi G; Bussolari R; Cafarelli L; Petak I; Rasini V; Veronesi E; De Santis G; Spano C; Tagliazzucchi M; Barti-Juhasz H; Scarabelli L; Bambi F; Frassoldati A; Rossi G; Casali C; Morandi U; Horwitz EM; Paolucci P; Conte P; Dominici M
    Cancer Res; 2010 May; 70(9):3718-29. PubMed ID: 20388793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells.
    Yang B; Wu X; Mao Y; Bao W; Gao L; Zhou P; Xie R; Zhou L; Zhu J
    Neurosurgery; 2009 Sep; 65(3):610-24; discussion 624. PubMed ID: 19687708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma.
    Kim SM; Lim JY; Park SI; Jeong CH; Oh JH; Jeong M; Oh W; Park SH; Sung YC; Jeun SS
    Cancer Res; 2008 Dec; 68(23):9614-23. PubMed ID: 19047138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro anti-myeloma activity of TRAIL-expressing adipose-derived mesenchymal stem cells.
    Ciavarella S; Grisendi G; Dominici M; Tucci M; Brunetti O; Dammacco F; Silvestris F
    Br J Haematol; 2012 Jun; 157(5):586-98. PubMed ID: 22420897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Irradiation enhances the tumor tropism and therapeutic potential of tumor necrosis factor-related apoptosis-inducing ligand-secreting human umbilical cord blood-derived mesenchymal stem cells in glioma therapy.
    Kim SM; Oh JH; Park SA; Ryu CH; Lim JY; Kim DS; Chang JW; Oh W; Jeun SS
    Stem Cells; 2010 Dec; 28(12):2217-28. PubMed ID: 20945331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells.
    Lashinger LM; Zhu K; Williams SA; Shrader M; Dinney CP; McConkey DJ
    Cancer Res; 2005 Jun; 65(11):4902-8. PubMed ID: 15930312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TRAIL-transduced multipotent mesenchymal stromal cells (TRAIL-MSC) overcome TRAIL resistance in selected CRC cell lines in vitro and in vivo.
    Mueller LP; Luetzkendorf J; Widder M; Nerger K; Caysa H; Mueller T
    Cancer Gene Ther; 2011 Apr; 18(4):229-39. PubMed ID: 21037557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting of XIAP combined with systemic mesenchymal stem cell-mediated delivery of sTRAIL ligand inhibits metastatic growth of pancreatic carcinoma cells.
    Mohr A; Albarenque SM; Deedigan L; Yu R; Reidy M; Fulda S; Zwacka RM
    Stem Cells; 2010 Nov; 28(11):2109-20. PubMed ID: 20882532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer gene therapy using a novel secretable trimeric TRAIL.
    Kim CY; Jeong M; Mushiake H; Kim BM; Kim WB; Ko JP; Kim MH; Kim M; Kim TH; Robbins PD; Billiar TR; Seol DW
    Gene Ther; 2006 Feb; 13(4):330-8. PubMed ID: 16195699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human bone marrow-derived mesenchymal stromal cells expressing S-TRAIL as a cellular delivery vehicle for human glioma therapy.
    Menon LG; Kelly K; Yang HW; Kim SK; Black PM; Carroll RS
    Stem Cells; 2009 Sep; 27(9):2320-30. PubMed ID: 19544410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppressing orthotopic pancreatic tumor growth with a fiber-modified adenovector expressing the TRAIL gene from the human telomerase reverse transcriptase promoter.
    Jacob D; Davis J; Zhu H; Zhang L; Teraishi F; Wu S; Marini FC; Fang B
    Clin Cancer Res; 2004 May; 10(10):3535-41. PubMed ID: 15161713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells.
    Hyer ML; Croxton R; Krajewska M; Krajewski S; Kress CL; Lu M; Suh N; Sporn MB; Cryns VL; Zapata JM; Reed JC
    Cancer Res; 2005 Jun; 65(11):4799-808. PubMed ID: 15930300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
    Singh TR; Shankar S; Chen X; Asim M; Srivastava RK
    Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stromal cells.
    Secchiero P; Melloni E; Corallini F; Beltrami AP; Alviano F; Milani D; D'Aurizio F; di Iasio MG; Cesselli D; Bagnara GP; Zauli G
    Stem Cells; 2008 Nov; 26(11):2955-63. PubMed ID: 18772312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene.
    Kagawa S; He C; Gu J; Koch P; Rha SJ; Roth JA; Curley SA; Stephens LC; Fang B
    Cancer Res; 2001 Apr; 61(8):3330-8. PubMed ID: 11309289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.
    Koschny R; Holland H; Sykora J; Haas TL; Sprick MR; Ganten TM; Krupp W; Bauer M; Ahnert P; Meixensberger J; Walczak H
    Clin Cancer Res; 2007 Jun; 13(11):3403-12. PubMed ID: 17545549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of tumor necrosis factor-related apoptosis-inducing ligand in interferon-induced apoptosis in human bladder cancer cells.
    Papageorgiou A; Lashinger L; Millikan R; Grossman HB; Benedict W; Dinney CP; McConkey DJ
    Cancer Res; 2004 Dec; 64(24):8973-9. PubMed ID: 15604261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro.
    Bai J; Sui J; Demirjian A; Vollmer CM; Marasco W; Callery MP
    Cancer Res; 2005 Mar; 65(6):2344-52. PubMed ID: 15781649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Expression of TRAIL(114-281) mediated by adeno-associated virus and its tumoricidal activity].
    Ma H; Liu YX; Liu SL; Xu RA; Zheng DX
    Zhonghua Yi Xue Za Zhi; 2004 Oct; 84(19):1635-41. PubMed ID: 15569460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of a novel recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand.
    Fang F; Wang AP; Yang SF
    Acta Pharmacol Sin; 2005 Nov; 26(11):1373-81. PubMed ID: 16225761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.